NMI 8000

Drug Profile

NMI 8000

Alternative Names: Mullerian inhibitory substance - Nemucore; NMI-8000; rhMIS - Nemucore

Latest Information Update: 17 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts General Hospital; Nemucore Medical Innovations
  • Developer Massachusetts General Hospital; Nemucore Medical Innovations; Pfenex
  • Class Proteins; Transforming growth factors
  • Mechanism of Action Anti-Mullerian hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gynaecological cancer; Ovarian cancer

Most Recent Events

  • 14 Dec 2015 Nemucore Medical Innovations in-licenses Expression Technology® for the production of NMI 8000 from Pfenex
  • 09 Dec 2015 Preclinical trials in Gynaecological cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top